Study of new drugs for moderate to severe ulcerative colitis or Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ulcerative colitis or Crohn's disease for at least 3 months.
- Your disease is currently moderate to severe (based on doctor's assessment and scope results).
- You have tried at least one standard treatment (like steroids, immunomodulators, or a biologic) and it didn't work well enough, stopped working, or caused side effects.
- You do not have IBD-unclassified, primary sclerosing cholangitis, or a history of certain bowel surgeries or complications.
- You have not failed more than 5 advanced treatments or an anti-IL-23 medicine before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking a new drug (LY4395089) with mirikizumab works better than mirikizumab alone for adults with Crohn's disease. It also looks at the safety of these treatments.
This trial tests new medicines for people with moderate to severe ulcerative colitis who haven't found relief with standard treatments. Participants will receive one of several investigational drugs (these are not yet approved and are being studied for safety and tolerability). The goal is to see if the drugs are safe and if they might help control symptoms.
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Hear when a new Colitis, Ulcerative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.